The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.
Cristina Cruz Zambrano
No relevant relationships to disclose
Khaldoun Almhanna
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Takeda
Jordi Rodon Ahnert
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
Jason Edward Faris
No relevant relationships to disclose
JungAh Jung
Employment or Leadership Position - Takeda
Adedigbo Fasanmade
Employment or Leadership Position - Takeda
Tim Wyant
Employment or Leadership Position - Takeda
Thea Kalebic
Employment or Leadership Position - Takeda
Stock Ownership - Takeda